DiaMedica Therapeutics (DMAC) Proxy filing summary

Executive summary

• Annual General Meeting scheduled for May 20, 2026, at the company’s Minneapolis headquarters.

• Shareholders are invited to vote on key proposals, including director elections and executive compensation.

Voting matters and shareholder proposals

• Election of seven directors to serve until the next Annual General Meeting or until successors are elected.

• Ratification of Baker Tilly US, LLP as independent auditor for the fiscal year ending December 31, 2026.

• Advisory (non-binding) vote to approve executive compensation.

• Approval of amendment and restatement of the 2019 Omnibus Incentive Plan.

• Other business may be transacted as properly brought before the meeting.

Board of directors and corporate governance

• Seven nominees for director positions: Michael Giuffre, Richard Kuntz, Tanya N. Lewis, Daniel J. O'Connor, James Parsons, Rick Pauls, and Charles Semba.

• Board recommends voting in favor of all director nominees.